Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Progress in targeting RAF kinases for cancer therapy.

Turbyville TJ, Holderfield M.

Per Med. 2015 Jun;12(3):183-186. doi: 10.2217/pme.15.1. No abstract available.

PMID:
29771643
2.

New weapons to penetrate the armor: Novel reagents and assays developed at the NCI RAS Initiative to enable discovery of RAS therapeutics.

Esposito D, Stephen AG, Turbyville TJ, Holderfield M.

Semin Cancer Biol. 2018 Feb 9. pii: S1044-579X(17)30279-1. doi: 10.1016/j.semcancer.2018.02.006. [Epub ahead of print] Review.

PMID:
29432816
3.

Efforts to Develop KRAS Inhibitors.

Holderfield M.

Cold Spring Harb Perspect Med. 2017 Nov 3. pii: a031864. doi: 10.1101/cshperspect.a031864. [Epub ahead of print]

PMID:
29101115
4.

RAS signaling: Divide and conquer.

Holderfield M, Morrison DK.

Nat Chem Biol. 2016 Dec 16;13(1):7-8. doi: 10.1038/nchembio.2264. No abstract available.

PMID:
27984577
5.

Inhibition of Ras/Raf/MEK/ERK Pathway Signaling by a Stress-Induced Phospho-Regulatory Circuit.

Ritt DA, Abreu-Blanco MT, Bindu L, Durrant DE, Zhou M, Specht SI, Stephen AG, Holderfield M, Morrison DK.

Mol Cell. 2016 Dec 1;64(5):875-887. doi: 10.1016/j.molcel.2016.10.029. Epub 2016 Nov 23.

6.

K-Ras Promotes Tumorigenicity through Suppression of Non-canonical Wnt Signaling.

Wang MT, Holderfield M, Galeas J, Delrosario R, To MD, Balmain A, McCormick F.

Cell. 2015 Nov 19;163(5):1237-1251. doi: 10.1016/j.cell.2015.10.041.

7.

Farnesylated and methylated KRAS4b: high yield production of protein suitable for biophysical studies of prenylated protein-lipid interactions.

Gillette WK, Esposito D, Abreu Blanco M, Alexander P, Bindu L, Bittner C, Chertov O, Frank PH, Grose C, Jones JE, Meng Z, Perkins S, Van Q, Ghirlando R, Fivash M, Nissley DV, McCormick F, Holderfield M, Stephen AG.

Sci Rep. 2015 Nov 2;5:15916. doi: 10.1038/srep15916.

8.

Transcriptome-wide characterization of the eIF4A signature highlights plasticity in translation regulation.

Rubio CA, Weisburd B, Holderfield M, Arias C, Fang E, DeRisi JL, Fanidi A.

Genome Biol. 2014;15(10):476.

9.

Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond.

Holderfield M, Deuker MM, McCormick F, McMahon M.

Nat Rev Cancer. 2014 Jul;14(7):455-67. doi: 10.1038/nrc3760. Review.

10.

Mechanism and consequences of RAF kinase activation by small-molecule inhibitors.

Holderfield M, Nagel TE, Stuart DD.

Br J Cancer. 2014 Aug 12;111(4):640-5. doi: 10.1038/bjc.2014.139. Epub 2014 Mar 18. Review.

11.

Interferon-induced transmembrane protein 1 regulates endothelial lumen formation during angiogenesis.

Popson SA, Ziegler ME, Chen X, Holderfield MT, Shaaban CI, Fong AH, Welch-Reardon KM, Papkoff J, Hughes CC.

Arterioscler Thromb Vasc Biol. 2014 May;34(5):1011-9. doi: 10.1161/ATVBAHA.114.303352. Epub 2014 Mar 6.

12.

Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors.

Holderfield M, Lorenzana E, Weisburd B, Lomovasky L, Boussemart L, Lacroix L, Tomasic G, Favre M, Vagner S, Robert C, Ghoddusi M, Daniel D, Pryer N, McCormick F, Stuart D.

Cancer Res. 2014 Apr 15;74(8):2238-45. doi: 10.1158/0008-5472.CAN-13-1065-T. Epub 2014 Feb 12.

13.

RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation.

Holderfield M, Merritt H, Chan J, Wallroth M, Tandeske L, Zhai H, Tellew J, Hardy S, Hekmat-Nejad M, Stuart DD, McCormick F, Nagel TE.

Cancer Cell. 2013 May 13;23(5):594-602. doi: 10.1016/j.ccr.2013.03.033.

14.

Crosstalk between vascular endothelial growth factor, notch, and transforming growth factor-beta in vascular morphogenesis.

Holderfield MT, Hughes CC.

Circ Res. 2008 Mar 28;102(6):637-52. doi: 10.1161/CIRCRESAHA.107.167171. Review.

15.

TNF primes endothelial cells for angiogenic sprouting by inducing a tip cell phenotype.

Sainson RC, Johnston DA, Chu HC, Holderfield MT, Nakatsu MN, Crampton SP, Davis J, Conn E, Hughes CC.

Blood. 2008 May 15;111(10):4997-5007. doi: 10.1182/blood-2007-08-108597. Epub 2008 Mar 12.

16.

HESR1/CHF2 suppresses VEGFR2 transcription independent of binding to E-boxes.

Holderfield MT, Henderson Anderson AM, Kokubo H, Chin MT, Johnson RL, Hughes CC.

Biochem Biophys Res Commun. 2006 Aug 4;346(3):637-48. Epub 2006 Jun 8.

PMID:
16782059
17.

Cell-autonomous notch signaling regulates endothelial cell branching and proliferation during vascular tubulogenesis.

Sainson RC, Aoto J, Nakatsu MN, Holderfield M, Conn E, Koller E, Hughes CC.

FASEB J. 2005 Jun;19(8):1027-9. Epub 2005 Mar 17.

PMID:
15774577

Supplemental Content

Loading ...
Support Center